Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

axalimogene filolisbac

A cancer vaccine containing a live-attenuated strain of the bacterium Listeria monocytogenes (Lm) encoding human papillomavirus (HPV) type 16 E7 fused to a non-hemolytic listeriolysin O protein with potential immunostimulatory and antineoplastic activities. Upon vaccination with axalimogene filolisbac, Listeria expresses the HPV 16 E7 antigen and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV 16 E7. This may result in tumor cell lysis. In addition, the Listeria vector itself may induce a potent immune response. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in the majority of cervical cancer cells.
Synonym:ADXS11-001 vaccine
attenuated live Listeria encoding HPV 16 E7 vaccine
attenuated live Listeria encoding HPV 16 E7 vaccine ADXS11-001
attenuated live Listeria encoding human papilloma virus 16 E7 vaccine
Lovaxin-C
US brand name:Lovaxin C
Code name:ADXS11-001
Lm-LLO-E7
Search NCI's Drug Dictionary